*Comprehensive biochemistry panel | Comprehensive biochemical profile | Assesses liver and kidney function, glucose, lipid profile, electrolytes and overall metabolism. | Request a hospital quote |
α-L-Fucosidase (AFU) | α-L-Fucosidase (AFU) assay | A clinician may interpret this alongside other tests in specific diagnostic or monitoring settings. It cannot diagnose or exclude cancer on its own and is not routine cancer screening for everyone without symptoms. | Request a hospital quote |
*Homocysteine | Homocysteine | Cardiovascular and cerebrovascular event risk modulation marker. | Request a hospital quote |
*Small dense low-density lipoprotein (sdLDL) | Small dense low-density lipoprotein (sdLDL) | Assists refined cardiovascular risk assessment. | Request a hospital quote |
*Glycated hemoglobin (HbA1c) | Glycated hemoglobin (HbA1c) | Mean glycemic control over ~2–3 months. | Request a hospital quote |
*Glycated albumin (GA) | Glycated albumin (GA) | Short-term glycemic control ~2–4 weeks. | Request a hospital quote |
*Free fatty acids | Free fatty acids | Evaluates adipose-derived energy flux. | Request a hospital quote |
*Cystatin C | Cystatin C | Glomerular filtration–linked renal function biomarker. | Request a hospital quote |
*Insulin | Fasting insulin | Assesses basal insulin secretion. | Request a hospital quote |
*Vitamin B12 | Vitamin B12 | Cofactor for homocysteine detoxification pathways; adjunct cardiovascular profiling. | Request a hospital quote |
*Folate | Folate | Nutritional and cardiovascular synergy assessment. | Request a hospital quote |
*Thyroid function panel (seven tests) | FT3, FT4, TT3, TT4, anti-TG, anti-TPO, TSH | Holistic thyroid autoimmune and hormonal status overview. | Request a hospital quote |
*Parathyroid hormone (PTH) | Parathyroid hormone (PTH) | Calcium–phosphate mineral axis regulation. | Request a hospital quote |
*Thyrotropin receptor antibodies (TRAb) | Thyrotropin receptor antibody assay | Autoimmune Graves disease ancillary testing. | Request a hospital quote |
*Serum iron | Serum iron | Iron sufficiency profiling. | Request a hospital quote |
*Ceruloplasmin | Ceruloplasmin (CER) | Inflammatory, hepato-renal and oncologic adjunct marker. | Request a hospital quote |
*25-Hydroxyvitamin D [25(OH)D] | 25-Hydroxyvitamin D | Bone health and immunity–linked vitamin status. | Request a hospital quote |
*Apolipoproteins | ApoA, ApoB | Lipoprotein particle risk stratification. | Request a hospital quote |
*Creatine kinase-MB isoenzyme (CK-MB) | Creatine kinase-MB isoenzyme (CK-MB) | Myocyte injury adjunct marker. | Request a hospital quote |
*Coagulation panel (four tests) | PT, APTT, fibrinogen, TT | Hemostatic pathway overview. | Request a hospital quote |
*Hepatic fibrosis panel (four biomarkers) | Hepatic fibrosis four-marker panel | Chronic liver disease staging adjunct. | Request a hospital quote |
*Allergen-specific IgE panel | Screening IgE antibodies to fourteen allergens | Atopy profiling. | Request a hospital quote |
*Rheumatoid and inflammatory arthritis serology | ASO, CRP, rheumatoid factor (RF) | Connective-tissue disorder surveillance. | Request a hospital quote |
*Thrombelastography (TEG)—standard assay | Thrombelastography, routine assay | Global thrombotic risk phenotyping. | Request a hospital quote |
*T lymphocyte subsets / immunophenotype | T-cell, NK-cell enumeration | Immune competency assessment. | Request a hospital quote |
*Secondary hypertension biomarker panel (four hormones) | Renin-angiotensin-aldosterone axis–related assays (four-test panel) | Endocrine-mediated hypertension differentiation. | Request a hospital quote |
*B-type natriuretic peptide (BNP) | B-type natriuretic peptide (BNP) | Heart failure biochemical signature. | Request a hospital quote |
*Epstein-Barr virus (EBV) serology | EBV antibody profile | Viral oncogenesis risk adjunct—nasopharyngeal carcinoma geography. | Request a hospital quote |
*Serum protein electrophoresis | Serum protein electrophoresis | Monoclonal gammopathy and systemic disorder screening adjunct. | Request a hospital quote |
*Trace elements and toxic metals seven-test panel | Serum copper, zinc, magnesium; urinary lead, mercury, arsenic plus random urine creatinine | Essential micronutrients and toxic heavy-metal exposure screening. | Request a hospital quote |
*Oxidized low-density lipoprotein (OxLDL) | Oxidized low-density lipoprotein cholesterol | Atherogenic oxidized LDL quantification. | Request a hospital quote |
*Apolipoprotein A-II (apoA-II) | Apolipoprotein A-II (apoA-II) | Lipoprotein subclass risk correlation. | Request a hospital quote |
*Human epididymis protein 4 (HE4) Applicability: Female only | Human epididymis protein 4 (HE4) | A clinician may interpret this alongside other tests in specific diagnostic or monitoring settings. It cannot diagnose or exclude cancer on its own and is not routine cancer screening for everyone without symptoms. | Request a hospital quote |
*Apolipoprotein E (apoE) | Apolipoprotein E (apoE) | Neuro-degenerative and atherogenic polygenic phenotype associations. | Request a hospital quote |
*Bone turnover markers (three tests) | Osteocalcin, β-CTX, total-P1NP | Anabolic versus catabolic bone remodeling balance. | Request a hospital quote |
*Reproductive hormone panel | Male: prolactin (PRL), testosterone (T), estradiol (E2), FSH, LH; female: prolactin (PRL), progesterone (P), testosterone (T), estradiol (E2) | Gonadal and pituitary hormone axis characterization. | Request a hospital quote |
*Expanded tumor marker panel | CEA, AFP, SCC, PGI, PGII, CA19-9, cytokeratin 19 fragment (Cyfra 21-1), ProGRP, CA125, NSE, CA72-4, CA15-3, ferritin (Ferritin); males additionally TPSA, FPSA | A clinician may interpret this alongside other tests in specific diagnostic or monitoring settings. It cannot diagnose or exclude cancer on its own and is not routine cancer screening for everyone without symptoms. | Request a hospital quote |